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SUMMARY – Therapeutic plasma exchange (TPE) is an extracorporeal blood purification tech-
nique, which removes large molecular weight particles such as autoantibodies from plasma. TPE is 
accepted by the American Society for Apheresis as first line treatment for some severe neuroimmune 
disorders. Double filtration plasmapheresis (DFPP) is a newer technique in which plasma is not en-
tirely removed, only the antibodies, using special filters. High-dose intravenous immunoglobulins are 
an alternative treatment for these patients but are much more expensive. We reviewed medical records 
of 20 patients with severe neurological diseases requiring TPE or DFPP. We analyzed the indications, 
complications and efficacy of these procedures. After completing the procedures, neurological im-
provement was recorded in 80% of the patients, 5% had no improvement, and the mortality was 15%. 
The rate of neurological improvement was similar to other studies. None of the patients presented 
catheter related complications. Systemic complications were mild, transient and completely reversible.
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Introduction
Therapeutic plasma exchange (TPE) is an extra-
corporeal blood purification technique designed to re-
move large molecular weight particles from plasma. 
The principal mechanism of action consists of remov-
ing circulating autoantibodies, immune complexes, cy-
tokines, monoclonal proteins, toxins and other inflam-
matory mediators1.This procedure is clinically avail-
able from the early 1970s for the treatment of several 
neuroimmune disorders2. Removing these pathogenic 
substances from patient plasma, in recent years this 
procedure has been increasingly indicated for hemato-
logic, neurological, connective tissue, nephrologic and 
metabolic disorders3. Double filtration plasmapheresis 
(DFPP) is a newer technique in which plasma is not 
entirely removed, only the antibodies, using special fil-
ters. Recent reports claim TPE to have numerous im-
munomodulatory effects4. Plasmapheresis is accepted 
as first line treatment, according to the American So-
ciety for Apheresis (ASFA) 2013 guidelines3, for the 
following neuroimmune disorders: Guillain-Barré 
syndrome (GBS), myasthenia gravis in severe crisis, 
chronic inflammatory demyelinating polyneuropathy 
and fulminant forms of Wilson disease. Plasmaphere-
sis is accepted as second line therapy in Lambert-Ea-
ton myasthenic syndrome, multiple sclerosis relapsing-
remitting form, acute disseminated encephalomyelitis 
(ADEM) and in neuromyelitis optica (NMO) unre-
sponsive to high-dose corticosteroids.
High-dose intravenous immunoglobulins (IVIG) 
represent an alternative treatment for severe neuroim-
mune disorders. According to ASFA guidelines, the 
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efficiency is equal for both treatments3. Many physi-
cians prefer IVIG because administration is easy, safe 
and involves few complications5,6, but IVIG is very ex-
pensive and is not covered by governmental health in-
surance in many countries7,8.
Materials and Methods
We retrospectively reviewed medical records of 20 
patients with severe autoimmune neurological diseases 
requiring TPE or DFPP, treated in our hospital during 
a 4-year period (from November 2012 to December 
2016). We analyzed the indications, side effects, com-
plications and efficacy of those procedures in these pa-
tients. The study was approved by the Ethics Board of 
the County University Emergency Hospital Sibiu 
(SCJU Sibiu). All patients signed an informed consent 
form prior to the procedure (after the procedural risks 
being explained in detail by a senior physician).
The patients were admitted to the Intensive Care 
Unit (ICU) until the procedures were over. The right 
internal jugular vein was catheterized with a 20 F dou-
ble lumen catheter in 18 patients and the left internal 
jugular vein was catheterized with a 20 F double lu-
men catheter in two patients. This procedure was per-
formed under local anesthesia, with an aseptic tech-
nique. X-ray control was performed to assure proper 
position of the catheter.
To remove autoantibodies, we used 2 techniques, 
TPE and DFPP, using the HF440 machine (Infomed 
SA, Geneva, Switzerland) for both. Cascade filtration 
is a 2-step process during which plasma is first extract-
ed from the blood and then circulated through a sec-
ond filter, plasma fractionator. Having a membrane 
pore size approximately 10-fold smaller than a plas-
mafilter, the plasma fractionator retains larger mole-
cules such as immunoglobulin G (IgG), low-density 
lipoprotein (LDL)-cholesterol and viruses. The plasma 
is filtered and then returned to the patient, thus avoid-
ing or minimizing the need for replacement fluids. The 
process can be named double filtration or DFPP 
(Double Filtration PlasmaPheresis).
The extracted plasma volume was calculated indi-
vidually, using Nadler’s formula and hematocrit, in a 
range of 1.5 total plasma volume/session. For TPE, we 
used a Granopen 060 Plasmafilter (Infomed SA, Ge-
neva, Switzerland). As volume replacement fluids, we 
used a mixture of fresh frozen plasma (FFP) 800-900 
mL, hydroxy ethyl starch (HES) 6% solution 1000 mL 
and 4% solution of human albumin (20% solution di-
luted in saline) to make up to the desired volume. 
DFPP was performed using a Granopen 060 Plas-
mafilter and Medopen 30 Plasmaseparator (Infomed 
SA, Geneva, Switzerland), with no necessity of replace-
ment fluids. A session was usually performed within 
2.5 to 6 hours depending on blood flow through the 
machine and plasma exchange rate, and repeated every 
24-48 hours depending on the neurological status.
Results and Discussion
Twenty patients were included in the study and a 
total of 62 TPE procedures and 14 DFPP sessions 
were performed (Table 1). Of these 20 patients, 11 
(55%) were women and nine (45%) were men, median 
age 56 (range 13-85) years, with the following diagno-
ses: GBS in nine (45%), myasthenia gravis (MG) in 
four (20%) patients, neuromyelitis optica (NO) in one 
(5%) and chronic inflammatory demyelinating poly-
radiculoneuropathy (CIDP) in one (5%) patient. The 
remaining 25% of patients had the following diag-
noses: stiff-man syndrome, transverse myelitis, pro-
gressive form of multiple sclerosis, NMO spectrum 
disorders and West-Nile encephalitis in one patient 
each.
Ten (50%) of the 20 patients were treated with 
TPE and three (15%) with DFPP as first-line therapy, 
whereas nine (45%) patients received TPE and four 
(20%) received DFPP as second-line therapy. The 
mean number of TPE sessions/patient and DFPP ses-
sions/patient was 3.8 (range 3-4) and 2.5 (range 2-3), 
respectively. For TPE, a total of 219 human albumin 
20% solution vials and 274 bags of FFP were used as 
replacement fluids. Eight patients having benefited 
from TPE and DFPP sessions received steroid medi-
cation before plasma exchange (three patients with 
MG and one patient with CIDP, multiple sclerosis, 
stiff-man syndrome, NMO and NMO spectrum dis-
orders each). Other therapies (IVIG or immunosup-
pressive medication) were not used before administra-
tion of plasma exchange therapy (Table 2).
A total of 25 systemic complications associated 
with TPE and DFPP were recorded (Table 3). There 
were no local complications related to the central ve-
nous catheter. The most common systemic complica-
tions of plasma exchange were hypocalcemia in nine 
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Table 1. Number of TPE and DFPP sessions according to patient diagnoses











Age (median) 59 57 54 58 48 56
Sex (F/M) 3/6 1/0 2/2 1/0 4/1 11/9
TPE as first-line therapy (n) 8 - 1 - 1 10
TPE as second-line therapy (n) 1 1 2 1 4 9
Total TPE sessions (n) 30 3 11 4 14 62
DFPP as first-line therapy (n) 1 - - 1 - 2
DFPP as second-line therapy (n) 2 - 1 - 1 4
Total DFPP sessions (n) 7 - 3 1 3 14
TPE session/patient (mean) 4 3 3.5 4 4 3,8
DFPP session/patient (mean) 3 - 3 2 2 2.5
TPE = therapeutic plasma exchange; DFFP = double filtration plasmapheresis; GBS = Guillain-Barre syndrome; CIDP = chronic inflam-
matory demyelinating polyneuropathy; MG = myasthenia gravis; NMO = neuromyelitis optica; FFP = fresh frozen plasma
Table 2. Use of steroid therapy, IVIG and replacement fluids according to patient diagnoses











Responsive to treatment (n) 8 1 3 1 3 16
Steroid 0 1 3 1 3 8
IVIG - - - - - -
Replacement fluid (vials, n)
Albumin 100 6 57 13 43 219
FFP 143 14 47 18 52 274
IVIG = intravenous immunoglobulin; FFP = fresh frozen plasma; GBS = Guillain-Barre syndrome; CIDP = chronic inflammatory demy-
elinating polyneuropathy; MG = myasthenia gravis; NMO = neuromyelitis optica
Table 3. Complications according to patient diagnoses











Catheter related - - - - - -
Hypocalcemia 5 - 2 1 1 9
Hyponatremia 2 1 1 - - 4
Hypokalemia 3 - 2 - - 5















Death 1 - 1 - 1 3
GBS = Guillain-Barre syndrome; CIDP = chronic inflammatory demyelinating polyneuropathy; MG = myasthenia gravis; NMO = neu-
romyelitis optica
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(36%), hyponatremia in four (16%) and hypokalemia 
in five (20%) patients. These patients presented peri-
oral and limb paresthesias and muscle cramps; these 
were mild and transient and never required interrup-
tion of the plasma exchange session. Mild, transient 
hypotension (systolic blood pressure <100 mm Hg) 
occurred in two (8%) patients, with minimal or no 
symptoms. Infection/sepsis (generated by prolonged 
immobilization) developed in five (20%) patients. The 
complication rate was 32% in the total of 76 TPE and 
DFPP sessions.
No patient death was recorded during the plasma 
exchange procedures. Three patients died from septic 
shock secondary to bronchopneumonia, including one 
patient with GBS, West-Nile encephalitis and MG 
(aspiration pneumonia) each, late in the evolution of 
the disease (Table 3).
After completing the plasma exchange sessions, 
80% of the patients had clinical neurological improve-
ment, 5% had no improvement, and the mortality was 
15%.
Guillain-Barré syndrome is a major cause of acute 
generalized paralysis; 5% of patients with severe evolu-
tion develop respiratory failure that requires endotra-
cheal intubation and mechanical ventilation9. The pri-
mary pathogenesis is a presumed autoimmune attack 
on peripheral nerves10. In our study, we included nine 
patients with GBS with the following etiology: flu 
vaccine in one patient, enterocolitis in two patients 
and respiratory infections in six patients. International 
guidelines suggest TPE or IVIG as front line treat-
ment for severe GBS3. On the one hand, the efficiency 
of TPE and IVIG in GBS (both being equally effi-
cient) has been underlined by two Cochrane reviews9,11. 
On the other hand, IVIG treatment has proven to be 
twice as expensive in comparison with TPE, with sim-
ilar clinical response12. A recent study published by 
Kumar et al. presents a group of 17 patients with GBS, 
each of them receiving TPE, 82.35% of these having a 
positive clinical outcome13. In another study reported 
by Hahn et al., the TPE procedure was applied to 15 
patients with GBS and 12 (80%) had good outcome14. 
In our study, we had nine patients with GBS, and eight 
(88.8%) of them showed significant improvement af-
ter TPE, similar to the studies mentioned above.
Myasthenia gravis is another neuroimmune disor-
der, in which 15% to 20% of patients evolve with my-
asthenic crises (MC)15,16. MC is defined as acute respi-
ratory failure or bulbar weakness causing dysphagia, 
with a high risk of aspiration, requiring tracheal intu-
bation at ICU16. Literature reports claim that TPE 
and IVIG are both equally efficient in MC17. Kumar et 
al. report on a success rate of TPE in 11 (84.6%) of 13 
patients with MC13. In our group, there were four pa-
tients with MC, and three of them successfully recov-
ered after TPE. Some studies support DFPP in treat-
ing MC18. In our group, one patient with MC was 
successfully treated with 3 DFPP sessions, applied 
every other day.
The patients with RRMS and NMO had a 5-year 
evolution of the disease with slight response to corti-
costeroids and multiple relapses. Among the autoanti-
bodies that play a role in MS pathogenesis, most im-
portant are proteins involved in the composition of 
myelin sheath, i.e. myelin basic protein (MBP), myelin 
oligodendrocyte glycoprotein (MOG), myelin proteo-
lipid protein (PLP) and myelin-associated protein 
(MAG), this being the reason why the ASFA 2013 
guidelines recommend plasmapheresis as second-line 
therapy19. As far as NMO is concerned, the relapse 
treatment is IV methylprednisolone, and if it fails to 
improve the neurological status, plasma exchange must 
be considered. New studies even suggest combining 
IV methylprednisolone with plasma exchange in pa-
tients with severe disease20. The patient with myelitis 
was newly diagnosed and we decided to perform TPE 
due to the fact that his symptomatology did not re-
spond to corticotherapy.
Kaynar et al. report on a study involving 57 patients 
with neurological disorders that received an average of 
5 TPE, with general improvement in 82% of patients21. 
In our group of 20 patients, improvement was record-
ed in 80% of patients. They received a mean of 3.8 
TPE sessions, every other day.
In the above studies, the complications of TPE and 
DFPP were either local (related to venous catheter) or 
systemic (related to the TPE or DFPP procedure). In 
our study group, none of the patients developed cath-
eter related complications, while systemic complica-
tions were mild, transient and completely reversible, 
and did not require interruption of the procedure. 
Some patients complained of paresthesias and cramps 
due to electrolyte imbalances. According to the World 
Apheresis Registry Data 2003-2007, the incidence of 
these symptoms is 1.5%-9%22.
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Conclusions
The TPE and DFPP procedures provide first-line 
management in several neuroimmune disorders with 
severe evolution. In our study, the overall neurological 
improvement rate after TPE and DFPP procedures 
was 80%, with mild and manageable complications 
and without death generated directly by these proce-
dures. The alternative treatment to TPE and DFPP is 
high-dose IVIG, which is easy to administer but is 
more expensive and difficult to obtain in our hospital. 
To our knowledge, this report presents the largest 
study group in our country in which neurological pa-
tients were treated with TPE and DFPP. These thera-
peutic procedures are safe and efficient, provided that 
they are performed by experienced practitioners, and 
are much less expensive than IVIG while having the 
same efficiency.
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Sažetak
TERAPIJSKA IZMJENA PLAZME I PLAZMAFEREZA S DVOSTRUKIM FILTRIRANJEM  
U TEŠKIM NEUROIMUNIM BOLESTIMA
C. Roman-Filip, M-G. Catană, A. Bereanu, A. Lăzăroae, F. Gligor i M. Sava
Terapijska izmjena plazme (TIP) je izvantjelesna tehnika pročišćavanja krvi kojom se iz plazme uklanjaju čestice velike 
molekularne težine poput autoantijela. Američko udruženje za aferezu prihvatilo je TIP kao liječenje prvog izbora za neke 
teške neuroimune bolesti. Plazmafereza s dvostrukim filtriranjem (PFDF) je nova tehnika kojom se ne uklanja sva plazma, 
nego samo antitijela, i to pomoću specijalnih filtara. Visoke doze intravenskih imunoglobulina su alternativna terapija za ove 
bolesnike, ali su znatno skuplji. Pregledali smo medicinske zapise 20 bolesnika s teškim neurološkim bolestima koji su tre bali 
TIP ili PFDF. Analizirali smo indikacije, komplikacije i učinkovitost ovih postupaka. Nakon završetka postupaka poboljšanje 
neurološkog statusa zabilježeno je u 80% bolesnika, 5% ih nije imalo nikakvo poboljšanje, a smrtnost je bila 15%. Stopa 
 neurološkog poboljšanja bila je slična onoj opisanoj u drugim istraživanjima. Komplikacije povezane s kateterom nisu zabi-
lježene ni u jednog bolesnika. Sistemske komplikacije bile su blage, prolazne i u potpunosti reverzibilne.
Ključne riječi: Plazma, izmjena; Plazmafereza; Imunoglobulini, intravenski; Autoimune bolesti živčanog sustava
